Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  20.00 0.5% 4,050.00 2,099 08:00:06
Bid Price Offer Price High Price Low Price Open Price
4,000.00 4,100.00 4,050.00 4,050.00 4,050.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.31 8.23 139.41 29.1 211
Last Trade Time Trade Type Trade Size Trade Price Currency
12:54:41 O 25 4,065.00 GBX

Bioventix (BVXP) Latest News

More Bioventix News
Bioventix Investors    Bioventix Takeover Rumours

Bioventix (BVXP) Discussions and Chat

Bioventix Forums and Chat

Date Time Title Posts
31/3/202117:35Bioventix - Sheep Antibodies1,320
08/11/201613:07ShareSoc Supper in Brighton-

Add a New Thread

Bioventix (BVXP) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
11:54:424,065.00251,016.25O
11:20:184,075.00140.75O
11:04:314,050.0028111,380.50O
10:45:334,066.006243.96O
10:39:394,000.0087034,800.00O
View all Bioventix trades in real-time

Bioventix (BVXP) Top Chat Posts

DateSubject
15/4/2021
09:20
Bioventix Daily Update: Bioventix Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker BVXP. The last closing price for Bioventix was 4,030p.
Bioventix Plc has a 4 week average price of 4,030p and a 12 week average price of 2,260p.
The 1 year high share price is 4,500p while the 1 year low share price is currently 2,260p.
There are currently 5,209,333 shares in issue and the average daily traded volume is 4,151 shares. The market capitalisation of Bioventix Plc is £210,977,986.50.
31/3/2021
17:35
valustar1: I think Bioventix own 10% Intuitive Investments Group plc Investment in CardiNor AS Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £125,000 to acquire ordinary shares in CardiNor AS ("CardiNor"), representing a 1.8 per cent. interest in CardiNor's enlarged share capital. CardiNor is a Norwegian biotech company established in June 2015 to commercialise the development of secretoneurin ("SN"), an important new biomarker for cardiovascular disease ("CVD"). SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte handling. This unique biological function explains why SN presents as an independent and strong predictor of mortality in all major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis. CardiNor has completed development of a research assay based on immunoassay technology to measure SN in blood and the assay is under further clinical development, including to obtain a CE mark. More information can be found at: hxxps://cardinor.com/ . In the year ended 31 December 2020 , per CardiNor's unaudited management accounts, it achieved a loss after tax of approximately £141,000 and, as at 31 December 2020, had net assets of approximately £500,000, assuming an exchange rate of 11.87NOK/GBP.
29/3/2021
18:50
strollingmolby: Piedro, yes I initially thought there must be a mistake or exceptional adjustments made, but then recalled the last half-year results to Dec'19 were restated due to a sales rebate not being entered into the accounting system, a pretty silly mistake really and not clear how that could have happened. This is from the correction note on 31 March 2020: Correction - Unaudited Interim Results for the six months ended 31 December 2019 The Company has become aware that due to an administration error a sales rebate of $219k (£167k) was not entered into the accounting system. Consequently revenues for the six month period were £5.1m not the £5.3m as reported on 30 March 2020. Pre tax profits were £4.1m as opposed to £4.3m as previously stated. The cash figure and interim dividend remain unchanged. HTTPS://www.investegate.co.uk/bioventix-plc--bvxp-/prn/correction---interim-results/20200331174737P8321/
29/3/2021
14:45
energeticbacker: Investor's Champion comment: As always, Bioventix swiftly converted profits into cash, with the operating cash inflow £3.3m and free cash inflow £3.2m, leaving period end cash of £5.8m well able to support a 20% increase in the first interim dividend to 43p per share.
24/3/2021
15:47
apad: I decided that I remembered a pattern to BVXP at results time (Monday). It would go up beforehand and slump on the announcement - because it was the usual pattern. So, I would sell on Friday and buy back when it fell on Monday. I checked back over a couple of years and it isn’t the usual pattern - so I wont! Now what’ll happen is that it’ll fall back on the Monday announcement! apad
24/3/2021
08:48
altom: I am a new holder of BVXP. Pleasantly impressed by this thread. Sensible grown up chaps, golfers even, having a friendly chat. Some posters on other shares just mouth pointless obscenities. I also am a buy and hold investor rather than a trader. I seem to have bought this one at the wrong time, but I shall hang on and see what happens.
20/3/2021
13:34
housemartin2: Ha - yes spann_703, I am also a largely buy and hold investor. I too have mused about selling part of my holding with the intention of buying back on any weakness. In the end I decided against it, largely on the grounds that I have been pretty hopeless in both anticipating results and second guessing the market reaction to them in several cases recently. I also bought BVXP at an average of £8.06, have used up all my CGT allowance and so I would need a drop of almost £7 in the share price to make it worthwhile. Possible I know but just too much of a risk for me. (Yes also my second largest holding after BOTB !)
20/3/2021
13:15
spann_703: Housemartin2 as recent posts attest, I doubt you're the only one musing in such a fashion. I keep coming back to a line in the latest results; "we expect our business will revert to an established trajectory". To me this is foreshadowing a potential dip in the short-term, and I am wary about how the market will react to anything other than the usual growth from BVXP. Long-term I am still optimistic as to the company's prospects however. So eschewing my usual buy and hold strategy, I sold 50% of my holding over the past week. This is my second-largest holding behind BOTB, and I suspect what I am trying to do is mitigate some of the risk, and like APAD am looking to buy on any price weakness. I usually get these things wrong however, and the correct approach is probably to hold as usual. Interesting how long-term I think the company will do well, and yet devoid of any pressures I still sold half of my holding. Writing this down, it doesn't entirely seem like the rational thing to do; investing rationally is not always so easy.
20/3/2021
12:58
apad: I've been doing the same sort of speculating. At the current share price it takes 20 years of revenue to buy the company - an astoundingly high number. By comparison my other large holdings are: BOO is 3.2 years FEVR is 9 years TSTL is 9 years So, I too expect a setback on the results. BVXP is 16% of my portfolio, but I shall still buy more over 2021 if there is a decent price drop. GLA apad
20/3/2021
11:59
housemartin2: I think that these upcoming 1/2 year numbers will be more interesting than usual. I expect that there will have been a decline in the use of tests due to medical systems concentrating on Covid at the expense of other procedures. However people will still be having suspected heart attacks (Troponin). General tests for Vit D deficiency I would expect to have declined and not made up for any testing on Covid patients (there are other things to worry about with Covid patients even if Vit D deficiency may be present !) We could be in for a bit of a jolt (long BVXP)
27/1/2021
09:44
strollingmolby: David is welcome to continue posting such events on the thread as it is entirely relevant with BVXP being discussed there (this is why we are here after all), and also how some of us got to first hear of BVXP when the price was around £3. :) So... are we going to reach an all-time high this week?
Bioventix share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
BVXP
Bioventix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210415 12:33:01